Search

Most patients with type 2 diabetes mellitus develop cardiovascular disease (CVD), with substantial loss of life expectancy. Nonfatal CVD contributes greatly to excess healthcare costs and decreased quality of life in patients with diabetes. The current epidemic of obesity has raised expectations that CVD associated with type 2 diabetes will become an even greater public health challenge. Despite the importance of this health problem, there is a lack of definitive data on the effects of the intensive control of glycemia and other CVD risk factors on CVD event rates in patients with type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is a randomized, multicenter, double 2 x 2 factorial design study involving 10,251 middle-aged and older participants with type 2 diabetes who are at high risk for CVD events because of existing CVD or additional risk factors. ACCORD is testing the effects of 3 medical treatment strategies to reduce CVD morbidity and mortality. All participants are in the glycemia trial, which is testing the hypothesis that a therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of6.0% will reduce the rate of CVD events more than a strategy that targets an HbA1c level of 7.0%-7.9%. The lipid trial includes 5,518 of the participants, who receive either fenofibrate or placebo in a double-masked fashion to test the hypothesis of whether, in the context of good glycemic control, a therapeutic strategy that uses a fibrate to increase high-density lipoprotein cholesterol and lower triglyceride levels together with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) to lower low-density lipoprotein cholesterol will reduce the rate of CVD events compared with a strategy that uses a statin plus a placebo. The blood pressure trial includes the remaining 4,733 participants and tests the hypothesis that a therapeutic strategy that targets a systolic blood pressure of120 mm Hg in the context of good glycemic control will reduce the rate of CVD events compared with a strategy that targets a systolic blood pressure of140 mm Hg. The primary outcome measure for all 3 research questions is the first occurrence of a major CVD event, specifically nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Upon the expected completion of participant follow-up in 2009, the ACCORD trial should document for the first time the benefits and risks of intensive glucose control, intensive blood pressure control, and the combination of fibrate and statin drugs in managing blood lipids in high-risk patients with type 2 diabetes.

Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program.BackgroundThe Kidney Early Evaluation Program (KEEP 2.0) cross-sectional, community-based study, targeted individuals at increased risk for kidney disease and measured blood glucose, creatinine, and hemoglobin.MethodsKEEP 2.0 screening data were used to determine the prevalence of anemia by level of kidney function and diabetes status. Estimated glomerular filtration rate (EGFR) was calculated using serum creatinine values, and categorized as ≥90, 60–89, 30–59 and 50 years, and 125 mg/dL, or nonfasting glucose >200 mg/dL.ResultsData were available on 5380 participants screened from August 2000 through December 2001. Diabetes was present in 26.9% of participants, and anemia in 7.7%; 15.9% of participants had at least moderately reduced kidney function (EGFR

The incidence of cardiovascular disease (CVD) is very high in patients with chronic kidney (CKD) disease and in kidney transplant recipients. Indeed, available evidence for these patients suggests that the 10-year cumulative risk of coronary heart disease is at least 20%, or roughly equivalent to the risk seen in patients with previous CVD. Recently, the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) published guidelines for the diagnosis and treatment of dyslipidemias in patients with CKD, including transplant patients. It was the conclusion of this Work Group that the National Cholesterol Education Program Guidelines are generally applicable to patients with CKD, but that there are significant differences in the approach and treatment of dyslipidemias in patients with CKD compared with the general population. In the present document we present the guidelines generated by this workgroup as they apply to kidney transplant recipients. Evidence from the general population indicates that treatment of dyslipidemias reduces CVD, and evidence in kidney transplant patients suggests that judicious treatment can be safe and effective in improving dyslipidemias. Dyslipidemias are very common in CKD and in transplant patients. However, until recently there have been no adequately powered, randomized, controlled trials examining the effects of dyslipidemia treatment on CVD in patients with CKD. Since completion of the K/DOQI guidelines on dyslipidemia in CKD, the results of the Assessment of Lescol in Renal Transplantation (ALERT) Study have been presented and published. Based on information from randomized trials conducted in the general population and the single study conducted in kidney transplant patients, these guidelines, which are a modified version of the K/DOQI dyslipidemia guidelines, were developed to aid clinicians in the management of dyslipidemias in kidney transplant patients. These guidelines are divided into four sections. The first section (Introduction) provides the rationale for the guidelines, and describes the target population, scope, intended users, and methods. The second section presents guidelines on the assessment of dyslipidemias (guidelines 1-3), while the third section offers guidelines for the treatment of dyslipidemias (guidelines 4-5). The key guideline statements are supported mainly by data from studies in the general population, but there is an urgent need for additional studies in CKD and in transplant patients. Therefore, the last section outlines recommendations for research.

The Treatment of Mild Hypertension Trial was a randomized, double-blind clinical trial conducted from 1986 to 1992 comparing the efficacy of six antihypertensive treatment regimens in 902 participants with stage I hypertension. To satisfy a secondary objective of the study, follow-up information on mortality and cardiovascular morbidity was collected. For this objective the aim was to ascertain the vital and cardiovascular event status as of the last day of the trial. This was accomplished by inviting each participant to attend a closeout visit shortly after the closeout date. In addition to serving as verification of vital status, this visit allowed data collection on nonfatal events that occurred between the last clinic visit and the closeout date. During this visit the patient was unblinded to study medication and given a medical summary of their participation during the trial, as well as a bottle of open-label medication. The advantages of a closeout visit are discussed along with a call for studies to provide clearer definitions of lost to follow-up and censoring times used in life-table analyses, especially when the primary event includes both fatal and nonfatal events. Control Clin Trials 2001;22:56–61

The Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial is a randomized, prospective, double-blind, parallel-group, two-arm, actively controlled, multicenter, international 5-year clinical trial involving 15,000 patients. CONVINCE will compare the incidence of fatal or nonfatal myocardial infarction (MI), fatal or nonfatal stroke, or cardiovascular-disease-related death in two antihypertensive treatment regimens. One treatment arm begins with controlled onset-extended release (COER)-verapamil, which has its major antihypertensive effect 6-12 hours after administration. The other arm (standard of care (SOC)) begins with either hydrochlorothiazide (HCTZ) or atenolol, one of which is preselected by the investigator for an individual patient prior to randomization. Secondary objectives include comparisons of the regimens for each of the components of the primary endpoint (separately), death or hospitalization related to cardiovascular disease, efficacy in lowering blood pressure to goal, primary events occurring between 6 am and noon, all-cause mortality, withdrawals from blinded therapy, cancer, and hospitalizations due to bleeding. Patients may be enrolled if they are hypertensive and at least 55 years of age and have an established second risk factor for cardiovascular disease. Initial medications include COER-verapamil (180 mg/d), HCTZ (12.5 mg/d), or atenolol (50 mg/d). Initial doses are doubled if blood pressure (BP) does not reach goal (systolic BP140 mm and diastolic BP90 mm Hg). If BP is not controlled by the higher dose of the initial medication, HCTZ is added to COER-verapamil, or the SOC choice not initially selected is added in the SOC arm. An ACE-inhibitor is recommended (although nearly any open-label medication is allowed) as the third step for patients whose BP is not adequately controlled or who have a contraindication to one of the two SOC medications. Patients take two sets of tablets daily, one in the morning and one in the evening. Although most patients switch from an established antihypertensive medication to randomized treatment, untreated patients with stages I-III hypertension (SBP between 140 and 190 or DBP between 90 and 110 mm Hg) are eligible. Outcomes are monitored by an independent Data and Safety Monitoring Board. Enrollment began during the third quarter of 1996, and follow-up is to be completed in the third quarter of 2002.

Left ventricular hypertrophy (LVH) predicts cardiovascular risk in hypertensive patients. We analyzed baseline/follow-up electrocardiographies in 26,376 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial participants randomized to amlodipine (A), lisinopril (L), or chlorthalidone (C). Prevalent/incident LVH was examined using continuous and categorical classifications of Cornell voltage. At 2 and 4 years, prevalence of LVH in the C group (5.57%; 6.14%) was not statistically different from A group (2 years: 5.47%; P = .806, 4 years: 6.54%; P = .857) or L group (2 years: 5.64%; P = .857, 4 years: 6.50%; P = .430). Incident LVH followed similarly, with no difference at 2 years for C (2.99%) compared to A (2.57%; P = .173) or L (3.16%; P = .605) and at 4 years (C = 3.52%, A = 3.29%, L = 3.71%; P = .521 C vs. A, P = .618 C vs. L). Mean Cornell voltage decreased comparably across treatment groups (Δ baseline, 2 years = +3 to −27 μV, analysis of variance P = .8612; 4 years = +10 to −17 μV, analysis of variance P = .9692). We conclude that risk reductions associated with C treatment in secondary end points of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial cannot be attributed to differential improvements in electrocardiography LVH.

Background. Questions regarding the efficacy of nonpharmacologic approaches for the treatment of stage 1 hypertension were addressed as part of the Treatment of Mild Hypertension Study (TOMHS), a 4-year, randomized clinical trial (N = 902). This report describes the lifestyle intervention program used in TOMHS, presents data on the lifestyle changes observed, and focuses on the effect of weight loss on blood pressure and blood lipid levels. Methods. Participants were randomly assigned to receive either placebo or one of five different antihypertensive medications. All took part in a lifestyle intervention program to reduce weight and sodium and alcohol intake and to increase physical activity. Results. Substantial changes from baseline levels were achieved for all lifestyle intervention variables. Mean weight change was −10.5 lb (−5.6%) at 1 year, −8.5 lb (−4.5%) at 2 years, −7.4 lb (−4.0%) at 3 years, and −5.7 lb (−3.0%) at 4 years. At 4 years, 70% of participants remained below baseline weight and 34% maintained a weight loss of 10 lb or greater. Mean change in urinary sodium excretion was −12.5 mmol/8 hr (−23%) at 1 year, −10.7 mmol/8 hr (−20%) at 2 years, −8.4 mmol/8 hr (−16%) at 3 years, and −4.6 mmol/8 hr (−9%) at 4 years. Alcohol intake declined by 1.6 drinks/week among drinkers at 4 years. Reported leisure physical activity increased by 86% at 1 year and remained 50% above baseline at 4 years. Beneficial changes in blood pressure and serum lipids were associated with these changes. Conclusions. These results support a role for lifestyle interventions as the initial treatment for stage 1 hypertension and demonstrate that such interventions can be successfully implemented in the clinical setting.

Ventricular ectopic activity was recorded at baseline in 5.6% of the 12-lead electrocardiograms and 8.2% of the 2-minute rhythm strips of 4674 subjects with isolated systolic hypertension (systolic blood pressure 160 to 219 mm Hg, diastolic blood pressure 10 VPB on the 2-minute rhythm strip. Correlates of VPB presence on the 12-lead ECG were older-age male sex, presence of Q/QS pattern and higher heart rate. Participants with serum potassium < 3.5 mmol/L had a higher prevalence of VPB. Similarly, the number of VPB on the 2-minute rhythm strip was associated with male sex, increasing age, with lower serum potassium, history of palpitations, and presence of Q/QS patterns.

In conclusion, the WBC count has been demon-strated in several epidemiologic studies to be a strong independent predictor of future coronary heart disease. Although it is not possible at this point in time to be certain that the elevated WBC count is a cause rather than a consequence of ischemic heart disease, recent pathophysiologic studies suggest that the white blood cell, in particular the neutrophil, is instrumental in the pathogenesis of myocardial ischemia. It is conceivable that patients who develop acute myocardial ischemia have abnormal leukocyte function before the onset of the acute event, which provides a pathophysiologic milieu for the progression of the atherosclerotic process. Future research must focus on further elucidation of the properties of WBCs and clarification of the role of the activated neutrophil in the process of vascular injury. Quantitative and qualitative changes in leukocyte function may have important implications in the development of CHD.

Background. The degree of maintenance of risk factor changes observed in post-trial follow-up of participants in the Multiple Risk Factor Intervention Trial (MRFIT) provides insights into long-term determinants of preventive behaviors, as well as post-trial mortality differentials. Methods. Nine hundred eighty-nine former MRFIT participants at four clinical centers were invited to be reexamined 2–3.5 years after the end of this 6- to 8-year trial. Seventy percent came to the clinics for measurements of systolic and diastolic blood pressure, plasma lipids and lipoproteins, serum thiocyanate, and dietary food frequency. With the addition of phone interviews, 82% provided self-report data on cigarette smoking and use of antihypertensive drugs. Results. Comparison of Special Intervention (SI) and Usual Care (UC) groups showed that differences persisted for total (6.5 mg/dl, P = 0.02) and low-density lipoprotein cholesterol (5.4 mg/dl, P = 0.04), and for diastolic blood pressure (1.6 mm Hg, P = 0.02). Differences were not significant for systolic blood pressure (1.8 mm Hg, P = 0.12), cigarette smoking, and serum thiocyanate. The plasma cholesterol difference represented 70% of the value at the end of intervention, and food frequency profiles were consistent with maintenance of an SI-UC difference. Loss of the SI-UC difference in smoking was attributable to both UC cessation and SI recidivism. The blood pressure difference was not attributable to different proportions of SI and UC men on medications, but possibly to differences in diuretic doses, use of multiple drugs, and adherence. There was a persisting contrast in use of specific diuretics, with more frequent use of chlorthalidone and less of hydrochlorothiazide in the SI group. Conclusion. These findings suggest that cholesterol-lowering dietary changes are self-sustaining, while smoking cessation is less so, and may require continued intervention. Finally, the SI-UC differences in use of specific diuretics remains one hypothesis for explaining a portion of post-trial mortality trends.

Summary In recent years, success in the management of hypertension has not been convincingly translated into a significant reduction in mortality rates due to coronary heart disease. One possible explanation is that adverse changes in plasma lipid levels that are produced by some of the antihypertensive drugs may increase the metabolic risk of coronary heart disease and offset the benefits of lowering blood pressure. Recently, α 1 -adrenergic inhibitors have received increased attention because of their ability not only to lower blood pressure but also to have a favorable effect on serum lipid levels. These agents may also play an important therapeutic role in reducing the threat of α 1 -adrenoceptor-induced arrhythmias in myocardialischemia. This review has described some of the clinical implications of α-adrenergic receptor inhibition in patients with essential hypertension. Particular attention has been given to the recently developed α 1 -adrenergic receptor antagonist, doxazosin, which in once-daily dosage produces sustained reductions in blood pressure by direct relaxation of the systemic arteriolar resistance vessels while favorably changing the plasma lipid profile. This agent is an important addition to the treatment regimens that are currently available for the treatment of high blood pressure.

Few large scale studies have evaluated long term effects of antihypertensive monotherapy (MT) versus placebo (P) on left ventricular (LV) systolic performance. Over a period of 4 years, 844 subjects with mild hypertension (mean BP: 140/91) without cardiac disease were treated with one of 5 MTs or P, all receiving nutritional-hygienic intervention. 2-D directed M-mode echocardiograms evaluated LV function at baseline, 3 months and annually through 4 years. Average changes over 4 years were compared between combined MT groups and P. Average decrease in BP was 15.9/12.3mmHg in the MT group and 9.1/8.6mmHg in the P group. for global systolic performance, stroke volume, ejection fraction, and fractional shortening (FS) increased with MT but decreased in P (p

There is considerable interest in the feasibility of incorporating nutritional and lifestyle changes into blood pressure treatment and cardiovascular disease risk reduction programs in clinical practice settings. TOMHS was a multi-center, randomized trial comparing a non-drug lifestyle intervention plus placebo with 5 groups receiving the lifestyle intervention plus one of five active antihypertensive drugs. Participants were 902 men and women, age 45–69, with mild hypertension (DPB 90–99mmHg.) All patients received diet and lifestyle intervention provided by registered dietitians through a series of group and individual sessions. The program included an initial 6 month intensive education program followed by at least quarterly individual assessment and counseling sessions with the dietitians. The goals were: weight loss ≥ 10lbs.; 25% reduction in dietary sodium; 150minutes/week of moderate physical activity (600kcal); LIFE STYLE CHANGES AT 1,2,3, AND 4 YEARS1 Year2 Years3 Years4 YearsWt. Loss(Lbs.)−10.5−8.5−7.4−5.9Urine Na(% chg)−23.0−20.0−16.0−9.0Alcohol(% chg)−29.0−29.9−29.0−31.0Activity(% chg)+83.0+75.0+64.0+46.0N =848838815803 In the patients receiving the lifestyle intervention alone (placebo group), SBP fell by 10.4 mmHg and DBP by 9.4 mmHg and DBP was controlled (

This article states that it is an error to withhold treatment of mild hypertension until the blood pressure increases or end-organ damage develops. In most hypertensive patients, stepped-care pharmacologic treatment, beginning with diuretics and adding additional agents if necessary, is a proven approach to lowering blood pressure and preventing disease.

The approach to management of cardiovascular risk factors has been greatly enhanced by the recent publication of results from several large intervention studies. This increased knowledge has led to rapid changes in perspective and to some controversies regarding cardiovascular risk management. The major cardiovascular disease risk factors are high blood pressure, elevated serum cholesterol, and cigarette smoking. In the past, physicians have paid little attention to the latter two factors, focusing primarily on severe hypertension. Initially, the pharmacologic treatment of hypertension consisted mostly of thiazide diuretics, since they were the only agents generally available that were well-tolerated by most patients. Over the past decade, however, new data from large-scale intervention studies and the development of many new classes of antihypertensive agents have considerably improved the approach to managing all three primary risk factors. Recently published results of major clinical trials are likely to further alter physicians' perspectives and influence their practice habits. This article proposes an approach to comprehensive risk management that simultaneously involves all the major risk factors, with emphasis on blood pressure and lipids. The rationale for this integrated approach is based on the following facts: Hypertension trials have not convincingly demonstrated that lowering blood pressure alone reduces the risk for coronary heart disease; Cholesterol lowering has been shown conclusively to reduce the risk of coronary heart disease; Several classes of antihypertensive agents have now been found to significantly affect blood lipids, either adversely or beneficially; and Past observational epidemiologic studies have shown a positive association between blood lipids (cholesterol and triglycerides) and blood pressure, implying that these two conditions commonly occur together. The background supporting these facts, as well as a practical approach to the treatment of hypertension that takes into consideration the management of blood lipids, is provided in this article.

The major risk factors for coronary heart disease remain high blood pressure, cigarette smoking, and abnormal serum lipid levels, including total cholesterol but more specifically elevated low-density lipoprotein cholesterol and reduced high-density lipoprotein cholesterol levels. Observations made from large-scale trials almost a decade ago suggested that commonly used antihypertensive agents, such as thiazide diuretics and beta-blockers, may adversely influence serum lipid levels. Over time, we realized that these lipid alterations persist long term and are of sufficient magnitude to potentially account for important differences in coronary heart disease risk reduction among various antihypertensive drug regimens. Considering recent National Cholesterol Education Program and Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommendations concerning lipid and blood pressure treatment, it is prudent and timely to rethink our approach to antihypertensive therapy in patients with abnormal serum lipid levels. Therefore, when lipids are a concern, appropriate dietary treatments should be advised and antihypertensive therapy that has a beneficial or neutral impact on serum lipid levels should be considered.

The Multiple Risk Factor Intervention Trial (MRFIT) was a randomized primary prevention trial designed to test the effect of multifactor intervention on mortality from coronary heart disease. Before randomization, men were seen at three screening visits to establish eligibility. A total of 361,662 men were screened, and 12,866 men were randomized, 866 more than the goal of 12,000. The total time required for planning and recruitment was 44 months. Eligibility rates and dropout or refusal rates between screening visits varied considerably among the 20 clinics that took part in MRFIT. The variation in eligibility rates resulted largely from subjective interpretation by the staff of the willingness of the men to participate in the study and to make risk factor changes. Cigarette smokers and blacks were more likely to discontinue their participation between screening exams. The ultimate success of the MRFIT recruitment is attributed to (1) the previous experience of investigators in screening large numbers of participants for clinical trials and similar epidemiologic investigations, (2) the identification at each clinic of one or more persons whose specific responsibility was recruitment, (3) the phased entry of clinics into the study, (4) routine monitoring and reporting of recruitment rates by the coordinating center, (5) regular discussion of recruitment successes and problems at the Steering Committee meetings, and (6) site visits to examine in detail recruitment problems.

A multicenter, randomized, controlled, double-blind U.S. trial is comparing the combined effects of diet treatment and 1 of 5 active drug regimens with diet treatment alone, for the long-term management of middle-aged adults with "mild" hypertension. Factors stimulating this trial are data documenting the high prevalence of mild hypertension in the adult population; mild hypertension's responsibility for a high proportion of morbidity and mortality attributable to hypertension overall; data from long-term hypertension intervention trials showing reduced morbidity and mortality of people with mild hypertension with use of either diuretics or beta blockers as step-1 therapy, and other trials that failed to demonstrate beneficial impact on morbidity and mortality, possibly due to residual questions concerning aspects of benefit to risk ratios with these medications; recent data from trials showing long-term control of mild hypertension and other risk factors by nutritional means; lack of data from long-term trials on benefit to risk ratios with newer drugs such as selective alpha 1 inhibitors, angiotensin converting enzyme inhibitors and calcium channel blockers; paucity of data from trials on long-term combined effects of diet and drug therapy, and of diet alone, for people with mild hypertension. During the next few years, phase 1 of the trial will study 6 groups of drugs. The step-1 drugs are angiotensin converting enzyme inhibitor (enalapril), alpha 1 inhibitor (doxazosin), beta blocker (acebutolol), calcium channel blocker (amlodipine), diuretic (chlorthalidone) and placebo. All participants are to receive vigorous sustained nutritional counseling to reduce obesity, moderate sodium intake and avoid heavy use of alcohol. Key endpoints for phase 1 of the study are the need for additional medication to control mild hypertension, side effects (i.e., clinical and biochemical) and consequent need to discontinue drug and quality of life. Phase-1 data are to be used to complete the phase-2 design, with the ultimate aim to assess effects on morbidity and mortality.

Smoking status of spouses/partners and other social contacts was examined among 5,241 adults who had recently visited a family physician. Associations between smoking status and proportion of social contacts who smoke among men and women of three different age groups were assessed by analysis of covariance, with age and education as covariates. The proportion of smoking contacts was found to be greatest for smokers, less for ex-smokers, and least for never smokers. Comparison of data across four types of social contacts by smoking groups suggests that, in general, the social contacts of ex-smokers more strongly resemble those of never smokers than those of current smokers. The results suggest that smokers desiring to become nonsmokers need to enlarge their social group to include more nonsmoking contacts, as well as to learn and use coping strategies to prevent relapse in the presence of smokers.

Within a community-wide heart disease prevention effort, it was hypothesized that personalized risk factor screening and education would result in modified health behaviors and reduced risk factor levels for coronary heart disease. Adults from a population sample were randomized to a community-wide screening and education program or were excluded from that program for 1 year. At the end of that year, both groups were measured for risk factor levels and related health behaviors. Those who received the screening and education program had significantly lower risk factor levels and other evidence of health behavior change, including lower blood cholesterol (206.9 vs 211.5 mg/dl), lower diastolic blood pressure (68.7 vs 70.0 mm Hg), lower resting heart rate (71.4 vs 72.7 bpm), and increased selection of low-fat and low-sodium meals in local restaurants. These data suggest that systematic risk factor screening and education may result in lower population risk for coronary heart disease.

The MRFIT blood pressure data derived from the Special Intervention (SI) group of men over the first 4 years are presented, and the results of the hypertension treatment program are reviewed. A therapeutic goal diastolic blood pressure (DBP) was established for each man determined to be hypertensive which included men with DBP ⩾90 mm Hg and men who were already taking antihypertensive drugs. A stepped care protocol was used to guide the drug treatment. At the fourth annual examination, 63.8% of the 5,790 SI men seen had been previously declared hypertensive. The mean baseline blood pressure (BP) for the hypertensive group was 140.3 mm Hg, systolic, and 94.5 mm Hg, diastolic, and at the 48-month visit, the mean BP was 120.7 mm Hg, systolic, and 82.5 mm Hg, diastolic. Of the hypertensive men seen at 48 months, 87.3% were taking antihypertensive drugs, 65.4% were at or below their goal pressure, and 83.5% had a DBP

The results of several important clinical trials have confirmed the benefits of pharmacologic treatment in patients with hypertension. However, some issues concerning this type of treatment have yet to be resolved. For example, it has not been determined whether there are differences among antihypertensive agents with respect to their effects on mortality and morbidity or whether such effects are independent of the alterations in blood pressure resulting from the use of such agents. Thiazide diuretics, the most commonly prescribed antihypertensive drugs, were the first agents proven to be effective and practical for the widespread treatment of hypertension. Alpha blockers, also commonly prescribed antihypertensive drugs, provide equally effective blood pressure control to that of the thiazides, but with a very different metabolic profile. In this article, these drugs are compared for efficacy, side-effect profiles, metabolic effects, and potential for reducing the risk of coronary heart disease.

Ability to safely withdraw well-controlled mild hypertensives from drugs is being tested in a three-group randomized trial. Group I (intervention) was removed from drugs after the first 2 months of nutrition counseling. Counseling is continuing through the remaining years of the trial to achieve a minimum weight loss of 10 lb if overweight, reduction of sodium intake to less than 1,800 mg, and reduction of alcohol intake to not more than two drinks per day. Group II (the first control group) was also removed from drugs to see if previous long-term blood pressure control had a carryover effect without dietary change. Blood pressure is monitored frequently in both groups, with return to drug treatment in the event of specified blood pressure rise. Group III (the second control group) has remained on drugs for comparison of blood pressure and biochemical variables. In Group I mean 30-month weight loss was 8 lb, with 35% losing 10+ lb; sodium intake was reduced by 38%. Blood pressure control without drugs was maintained for 47% of Group I patients but only 16% of group II patients (P less than 0.05). These findings indicate it may be possible, after establishing good blood pressure control, to maintain control in a sizable proportion without medication, when reduction of weight, sodium, and alcohol intake is achieved.